Published on Mar 22, 2023
FTC staff reviewing Amgen’s (AMGN) proposed $27.8 billion acquisition of Horizon Therapeutics (HZNP) is probing the acquirer’s track record of raising drug prices and allegedly shielding its products from competition, sources familiar with the matter said. The staff is considering whether Amgen’s purchase of Horizon, a developer of treatments for rare autoimmune and severe inflammatory […]
Already have an account? Log in.
Copyright ©2025 The Capitol Forum. All Rights Reserved.
